Bastholt L, et al. - In this largest cohort of patients with metastatic melanoma worldwide comprising 464 Danish patients, high-dose (HD) interleukin-2 (IL-2) and interferon (IFN) was administered as first-line treatment between January 2007 and April 2014. Relevant data on all patients with no patients lost to follow-up was provided. Data have been gathered in a national database on the treatment of metastatic melanoma established since 2011. An objective response rate (ORR) to treatment with a median progression-free survival (PFS) of 3.4 months and a median overall survival (OS) of 14.2 months was achieved in 118 patients (25%). A subset of treated patients confirmed to have achieved long-term survival with HD IL-2/IFN as first-line therapy in metastatic melanoma. In patients with active melanoma, IL-2/IFN might represent a potential treatment option after established initial treatment with checkpoint inhibitors and BRAF/MEK-targeted therapies.